Portal de Periódicos da CAPES

Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study

2019; Multidisciplinary Digital Publishing Institute; Volume: 11; Issue: 7 Linguagem: Inglês

10.3390/cancers11070995

2072-6694

Shristi Bhattarai, Sergey Klimov, Karuna Mittal, Uma Krishnamurti, Xiaoxian Li, Gabriela Oprea‐Ilies, Ceyda Sönmez Wetherilt, Ansa Riaz, Mohammed A. Aleskandarany, Andrew R. Green, Ian O. Ellis, Guilherme Cantuaria, Meenakshi V. Gupta, Upender Manne, Johnson Agboola, Brett Baskovich, Emiel A. M. Janssen, Grace Callagy, Elaine M. Walsh, Anurag Mehta, Atika Dogra, Tanuja Shet, Pooja Gajaria, Tiffany A. Traina, Haruna Asura Nggada, Abidemi Omonisi, Saad Ahmed, Emad A. Rakha, Padmashree C.G. Rida, Ritu Aneja,

Cancer Risks and Factors

Background: The androgen receptor (AR) has emerged as a potential therapeutic target for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR’s prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients’ prognosis. Methods: We evaluated the prognostic value of AR in resected primary tumors from TNBC patients from six international cohorts {US (n = 420), UK (n = 239), Norway (n = 104), Ireland (n = 222), Nigeria (n = 180), and India (n = 242); total n = 1407}. All TNBC samples were stained with the same anti-AR antibody using the same immunohistochemistry protocol, and samples with ≥1% of AR-positive nuclei were deemed AR-positive TNBCs. Results: AR status shows population-specific patterns of association with patients’ overall survival after controlling for age, grade, population, and chemotherapy. We found AR-positive status to be a marker of good prognosis in US and Nigerian cohorts, a marker of poor prognosis in Norway, Ireland and Indian cohorts, and neutral in UK cohort. Conclusion: AR status, on its own, is not a reliable prognostic marker. More research to investigate molecular subtype composition among the different cohorts is warranted.